Although there are controversies about the role of NLRP3 inflammasome during the process of colitis in various knockout mice [11, 38–40], many studies has proved that pharmacological blockage of NLRP3 activation and/or NF-kB can obviously ameliorate DSS colitis [41–45]. The gene discussed is NFKB1; the disease is colitis.